Canada
Visbiome Extra Strength GI Care - 2 Pack
Visbiome Extra Strength GI Care - 2 Pack
For the dietary management of Advanced Ulcerative Colitis (UC) and Ileal Pouch Dietary Management.
-
900 billion CFU per packet -
Dosage Format: Powder -
30 packets per box
Couldn't load pickup availability
Free shipping on all orders within the continental United States.
Free shipping on all orders within the continental United States.
Money back guarantee if returned within 60 days of ship date.
Money back guarantee if returned within 60 days of ship date.
Description
High Potency Probiotic Medical Food for the Dietary Management of Dysbiosis
The Science Behind Your Gut
The Critical Nature of Research
The human gastrointestinal tract is home to trillions of organisms forming the complex bacterial community known as the gut microbiome.
Visbiome's probiotic blend, the De Simone Formulation, has been the subject of more than 100 clinical studies.
Years of continuous research
Our formulation has had numerous clinical studies proving its efficacy in the management of dysbiosis associated with the following conditions:
Irritable Bowel Syndrome (IBS)
- Reductions in bloating, flatulence & abdominal pain
- Reductions in gut permeability
Ulcerative Colitis (UC)
- Improvements in UC Activity Index Scores
- Reductions in frequency
Antibiotic-Associated Diarrhea (AAD)
- Reduction in antibiotic side effect
Ileal Pouch Management
- Decreased bowel frequency
Inside The Packet
Lactic Acid Bacteria
Inactive Ingredients
Shipping Policy
Explore Other Visbiome products
- Capsule
- 112.5 Billion CFU
- 60 Capsules
- Powder
- 450 Billion CFU
- 30 Packets
- Powder
- 900 Billion CFU
- 30 Packets
- Wild Berry Flavor Powder
- 225 Billion CFU
- 30 Packets
Clinical Studies
The Most Studied Multi-Strain Probiotic Available
Since it's invention in the late '90s, the De Simone formulation has been the included in more peer reviewed studies than any comparable formula.
Visbiome’s probiotic blend, the De Simone Formulation, has been the subject of more than 100 clinical studies.
Years of continuous research
The Critical Nature of Research
The human gastrointestinal (Gl) tract is home to trillions of organisms which form the complex bacterial community known as the gut microbiome.
Probiotics may increasingly be a key factor in protecting this intricate network from the disastrous effects of disease. However, formulas vary. Successes will ultimately depend on the specific bacterial strains utilized, the concentration of bacteria, the way in which strains are processed, and the quality of the strains used.
A Probiotic with Proven Relief
Our formulation has had numerous clinical studies proving its efficacy in the management of dysbiosis associated with the following conditions:
Irritable Bowel Syndrome (IBS)
- Reductions in bloating. flatulence & abdominal pain
- Reductions in gut permeability
Ulcerative Colitis (UC)
- Improvements in UC Activity Index Scores
- Reductions in frequency
Antibiotic-Associated Diarrhea (AAD)
- Reduction in antibiotic side effect
Ileal Pouch Management
- Decreased bowel frequency
- Kim et al. Neurogastroenterol Motil (2005) 17,1-10
- Kim et al. Alimentary Pharmacology Therapeutics 2003; 17:895-904
- Wong et al. Digestive Diseases and Sciences. 2014
- Bazzocchi et al. Digestive and Liver Diseases 2002; 34(2):S48-53.
- Guandalini et al. Journal of Pediatric Gastroenterology and Nutrition. 2010;51:24-30
- Staudacher et al. Gastroenterology 2017;153:936-947
- Ng S.C., et al. Journal of Gastroenterology and Hepatology 2013; 28(10):1624-31
- Boonma et al. Frontiers in Pain Research. 2021
- Kim SE, et al. Journal of Neurogastroenterol Motility. 2015 Jan 1, 21 111-20.
- Michail S, Kenche H. Probiotics Antimicro. Prot. 2011 3:1-7.
- Bibiloni et al. American Journal of Gastroenterology. 2005;100:1539-1546
- Tursi A, et al. Med Sci Monit. 2004;10:126-131. from Visbiome.com
- Huynh Hien Q, et al. Inflamm Bowel Dis 15: 760-768 (2009)
- Sood et al. Clinical Gastroenterology and Hepatology 2009;7:1202-1209
- Tursi A. et al. Am J Gastroenterol. 105:2218-27 (2010)
- Lee J., Moon G., et al. Korean J Gastroenterol Vol. 60 n. 2 94-101 (2012)
- Ng SC, et al. Inflamm Bowel Dis. 2010;16:1286–1298.
- Miele E, et al. American Journal of Gastroenterology. 2009;104:437–443.
- C.P. Selinger et al. Journal of Hospital Infection 2013 Jun;84(2):159-65.
- Gionchetti P, et al. Gastroenterology. 2000;119(2):305-309.
- Gionchetti P, et al. Gastroenterology. 2003b;124(5):1202-1209.
- Mimura T, et al. Gut. 2004;53(1):108 114.
- Pronio, et al. Inflamm Bowel Dis 2008;14:662–668